Abstract
Purpose To compare the prevalence of depression and substance use/abuse according to sexual orientation and sex among Brazilian adults.
Methods Data were obtained from a national health survey (PNS 2019). This study included participants aged 18 and over (N=85,859). Prevalence ratios were estimated using Poisson models stratified by sex, for the association between sexual orientation, depression, daily tobacco use, alcohol abuse and both substance use/abuse.
Results After controlling for covariates, gay men showed a higher prevalence of depression (APR=1.92, 95% CI 1.32; 2.80), daily tobacco use (APR=1.93, 95% CI 1.45; 2.56) and multiple substances use/abuse (APR=1.73, CI95% 1.14;2.62) than heterosexuals. Bisexual men showed higher prevalence of depression (APR=2.91, 95% CI 1.54; 5.53). Estimated prevalence ratios were even higher among women. Lesbians showed higher prevalence of binge drinking (APR=2.52, 95% CI 1.94; 3.27), heavy drinking (APR=3.36, 95% CI 2.39; 4.72), daily tobacco use (APR=2.66, 95% CI 1.74; 4.07) and multiple substances use/abuse (APR=4.35, 95% CI 2.35;8.07) than among heterosexuals. Among bisexual women, results were significant for all analyzed outcomes: depression (APR=2.32, 95% CI 1.72; 3.13), binge drinking (APR=2.52, 95% CI 1.94; 3.27), heavy drinking (APR=2.53, 95% CI 1.68; 3.81), daily tobacco use (APR=1.82, 95% CI 1.12;2.96) and multiple substances use/abuse (APR=3.23, 95% CI 1.72;6.05).
Conclusions Our results indicate that sexual minorities are more vulnerable to mental illness and substance use/abuse. This finding draws attention to the need for specific public policies aimed at this population and for a greater recognition and better management of these disorders by health professionals.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
https://www.ibge.gov.br/estatisticas/sociais/saude/9160-pesquisa-nacional-de-saude.html?=&t=microdados
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
